KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity

Poirel, Laurent; Vuillemin, Xavier; Juhas, Mario; Masseron, Amandine; Bechtel-Grosch, Ursina; Tiziani, Simon; Mancini, Stefano; Nordmann, Patrice

doi:10.1128/AAC.00321-20

Back

Journal article

+ 1 other files

KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity

Poirel, Laurent Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland
Vuillemin, Xavier Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Juhas, Mario Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Masseron, Amandine Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Bechtel-Grosch, Ursina Department of Trauma Surgery, University Hospital of Zürich, Zürich, Switzerland
Tiziani, Simon Institute of Intensive Medicine, University Hospital Zürich, University of Zürich, Zürich, Switzerland
Mancini, Stefano Institute of Medical Microbiology, University of Zürich, Zürich, Switzerland
Nordmann, Patrice Emerging Antibiotic Resistance Unit and Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Fribourg, Switzerland -

22.07.2020

Published in:

Antimicrobial Agents and Chemotherapy. - 2020, vol. 64, no. 8, p. 10.1128/aac.00321-20

English KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three- amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam, explaining the ceftazidime-avibactam resistance, and (iv) an association with a sharp reduction of its carbapenemase activity.

Faculty

Faculté des sciences et de médecine

Department

Médecine 3ème année

Language